Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

232.91USD
26 Mar 2019
Change (% chg)

$12.65 (+5.74%)
Prev Close
$220.26
Open
$221.92
Day's High
$233.71
Day's Low
$221.86
Volume
1,876,104
Avg. Vol
617,754
52-wk High
$388.67
52-wk Low
$216.13

Latest Key Developments (Source: Significant Developments)

Nightstar Therapeutics PLC Reaches Agreement To Be Acquired By Biogen
Monday, 4 Mar 2019 

March 4 (Reuters) - Nightstar Therapeutics PLC ::NIGHTSTAR THERAPEUTICS PLC REACHES AGREEMENT TO BE ACQUIRED BY BIOGEN.  Full Article

Biogen Announces Agreement To Acquire Nightstar Therapeutics
Monday, 4 Mar 2019 

March 4 (Reuters) - Biogen Inc ::BIOGEN ANNOUNCES AGREEMENT TO ACQUIRE NIGHTSTAR THERAPEUTICS TO ESTABLISH CLINICAL PIPELINE OF GENE THERAPY CANDIDATES IN OPHTHALMOLOGY.THIS OFFER REPRESENTS A TOTAL TRANSACTION VALUE OF APPROXIMATELY $800 MILLION ON A FULLY DILUTED BASIS.SAYS BIOGEN TO ACQUIRE NIGHTSTAR THERAPEUTICS FOR $25.50 PER SHARE.ACQUISITION OF NST IS PLANNED TO BE FUNDED THROUGH AVAILABLE CASH AND ACCOUNTED FOR AS AN ACQUISITION OF A BUSINESS.  Full Article

Alkermes And Biogen Announce U.S. FDA Acceptance Of Diroximel Fumarate New Drug Application For Multiple Sclerosis
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Biogen Inc ::ALKERMES AND BIOGEN ANNOUNCE U.S. FOOD AND DRUG ADMINISTRATION ACCEPTANCE OF DIROXIMEL FUMARATE NEW DRUG APPLICATION FOR MULTIPLE SCLEROSIS.BIOGEN INC - IF APPROVED, BIOGEN INTENDS TO MARKET DIROXIMEL FUMARATE UNDER BRAND NAME VUMERITY.BIOGEN INC - NDA HAS BEEN ASSIGNED A PDUFA (PRESCRIPTION DRUG USER FEE ACT) TARGET ACTION DATE IN Q4 OF 2019.BIOGEN INC - ALKERMES IS SEEKING APPROVAL OF DIROXIMEL FUMARATE UNDER 505(B)(2) REGULATORY PATHWAY, REFERENCING BIOGEN'S DIMETHYL FUMARATE DATA.  Full Article

Biogen Says Continues To Diligently Evaluate New Opportunities For More Potential Business Development And M&A
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Biogen Inc ::CEO SAYS CO CONTINUES TO DILIGENTLY EVALUATE NEW OPPORTUNITIES FOR MORE POTENTIAL BUSINESS DEVELOPMENT AND M&A - CONF CALL.EXPECTS PHASE 3 DATA FOR ALZHEIMER'S TREATMENT ADUCANUMAB IN EARLY 2020 - CONF CALL.CFO SAYS EXPECTS GLOBAL SPINRAZA REVENUE TO BE RELATIVELY STABLE IN Q1, 2019 VERSUS Q4, 2018 - CONF CALL.CFO EXPECTS 2019 GLOBAL SPINRAZA REVENUES TO GROW IN MID-TO HIGH-TEENS - CONF CALL.CFO EXPECTS DOUBLE-DIGIT REVENUE GROWTH IN BIOSIMILAR BUSINESS IN 2019, PRIMARILY DRIVEN BY LAUNCH OF IMRALDI - CONF CALL.SAYS MULTIPLE SCLEROSIS BUSINESS GROWTH TRENDS TO CONTINUE IN 2019; EXPECTS PRICING PRESSURES OUTSIDE THE U.S. - CONF CALL.  Full Article

Biogen Expect 2019 Capital Expenditures To Be $500 Mln-$600 Mln
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Biogen Inc ::BIOGEN INC - EXPECT 2019 CAPITAL EXPENDITURES TO BE $500 MILLION-$600 MILLION.  Full Article

Biogen Reports Q4 Adj. EPS Of $6.99
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Biogen Inc ::BIOGEN - QTRLY NON-GAAP DILUTED EPS $6.99.QTRLY GAAP DILUTED EPS $4.73.QTRLY TECFIDERA REVENUE OF $1,110 MILLION VERSUS $1,076 MILLION REPORTED LAST YEAR.QTRLY TOTAL REVENUES $3,526 MILLION VERSUS $3,307 MILLION.QTRLY TYSABRI REVENUE OF $464 MILLION VERSUS $463 MILLION REPORTED LAST YEAR.SEES 2019 REVENUE TO BE APPROXIMATELY $13.6 BILLION TO $13.8 BILLION.QTRLY SPINRAZA REVENUE OF $470 MILLION VERSUS $363 MILLION.Q4 EARNINGS PER SHARE VIEW $6.73, REVENUE VIEW $3.39 BILLION -- REFINITIV IBES DATA.BIOGEN - 2019 NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $28.00 AND $29.00.SEES 2019 GAAP DILUTED EPS TO BE BETWEEN $26.65 & $27.65.FY2019 EARNINGS PER SHARE VIEW $27.94, REVENUE VIEW $13.64 BILLION -- REFINITIV IBES DATA.BIOGEN - IN Q4 2018 BOOKED GAAP-ONLY TAX CHARGE OF $136 MILLION RELATED TO INITIAL RECOGNITION OF DEFERRED TAXES ON GILTI TAX OF INTERNATIONAL EARNINGS.SEES 2019 RESEARCH AND DEVELOPMENT EXPENSE 16 TO 17 PERCENT OF REVENUES.  Full Article

Banner Gets FDA Tentative Approval For Multiple Sclerosis Treatment Bafiertam
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Biogen Inc ::BANNER RECEIVES FDA TENTATIVE APPROVAL FOR BAFIERTAM FOR THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS.BANNER LIFE SCIENCES LLC SAYS FULL APPROVAL EXPECTED NO LATER THAN JUNE 20, 2020.  Full Article

Alkermes And Biogen Announce Submission Of A New Drug Application To FDA For Diroximel Fumarate In Multiple Sclerosis
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Biogen Inc ::ALKERMES AND BIOGEN ANNOUNCE SUBMISSION OF A NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR DIROXIMEL FUMARATE IN MULTIPLE SCLEROSIS.BIOGEN INC - IF APPROVED, BIOGEN INTENDS TO MARKET DIROXIMEL FUMARATE UNDER BRAND NAME VUMERITY™.BIOGEN INC - VUMERITY™ NAME HAS BEEN CONDITIONALLY ACCEPTED BY FDA & WILL BE CONFIRMED UPON APPROVAL.  Full Article

AGTC Reports Topline Interim 6 Month Data From Phase 1/2 X-Linked Retinoschisis Clinical Study
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Applied Genetic Technologies Corp ::AGTC ANNOUNCES TOPLINE INTERIM SIX-MONTH DATA FROM PHASE 1/2 X-LINKED RETINOSCHISIS CLINICAL STUDY; TERMINATION OF BIOGEN COLLABORATION.APPLIED GENETIC- RESULTS FROM STUDY SHOW RAAV2TYF-CB-HRS1 GENERALLY SAFE, WELL-TOLERATED, BUT NO SIGNS OF CLINICAL ACTIVITY WERE OBSERVED AT 6-MONTHS.APPLIED GENETIC TECHNOLOGIES - TO REGAIN RIGHTS TO FIVE CLINICAL AND PRECLINICAL DEVELOPMENT PROGRAMS; BIOGEN TERMINATES COLLABORATION AGREEMENT.APPLIED GENETIC TECHNOLOGIES - TO REGAIN RIGHTS TO FIVE CLINICAL & PRECLINICAL DEVELOPMENT PROGRAMS; BIOGEN TERMINATES COLLABORATION AGREEMENT.APPLIED GENETIC - ON SCHEDULE TO ADVANCE ITS PHASE 1/2 CLINICAL STUDIES IN ACHROMATOPSIA,X-LINKED RETINITIS PIGMENTOSA; 3 DATA RELEASES SEEN IN 2019.APPLIED GENETIC TECHNOLOGIES CORP - BIOGEN'S TERMINATION OF COLLABORATION AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2019.APPLIED GENETIC TECHNOLOGIES - WILL DETERMINE NEXT STEPS FOR THREE DISCOVERY PROGRAMS OVER NEXT SEVERAL MONTHS.APPLIED GENETIC TECHNOLOGIES - PREVIOUS FINANCIAL GUIDANCE, EVEN IN LIGHT OF BIOGEN'S TERMINATION OF COLLABORATION AGREEMENT, REMAINS UNCHANGED.APPLIED GENETIC TECHNOLOGIES CORP - AS OF SEPT 30, 2018, CO'S CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $105.4 MILLION.APPLIED GENETIC TECHNOLOGIES - EXPECTS TOTAL CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF JUNE 30, 2019, TO BE BETWEEN $65 AND $75 MILLION.  Full Article

HitGen And Biogen Enter Research Collaboration
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Biogen Inc ::HITGEN AND BIOGEN ENTER A DNA-ENCODED LIBRARY-BASED DRUG DISCOVERY RESEARCH COLLABORATION.HITGEN - SPECIFIC FINANCIAL DETAILS WERE NOT DISCLOSED.HITGEN - WILL RECEIVE UPFRONT PAYMENTS, AND BE ELIGIBLE FOR MILESTONE PAYMENTS.  Full Article

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen Inc said on Monday it would buy back shares worth $5 billion (3.8 billion pounds), days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.